Results 261 to 270 of about 181,578 (308)

Diurnal rhythm in chimeric antigen receptor T cell effectiveness in an observational study of 715 patients. [PDF]

JCI Insight
Lyons PG, Gill E, Kumar P, Beasley M, Park-Egan B, Lokhandwala ZA, Lebold KM, Hayes-Lattin B, Hough CL, Singh N, Hazan G, Mok H, Huss JM, McEvoy CA, Haspel JA.   +14 more
europepmc   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Chimeric Antigen Receptor Therapy for Cancer [PDF]

Annual Review of Medicine, 2014
Improved outcomes for patients with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical, and clinical arenas spanning cellular immunology, synthetic biology, and cell-processing technologies has paved the way for clinical applications of chimeric antigen receptor ...
David M Barrett, Nathan Singh, David L Porter   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Chimeric Antigen Receptor Design Today and Tomorrow

The Cancer Journal, 2021
Abstract The US Food and Drug Administration has approved 3 chimeric antigen receptor (CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This includes different antigen-binding domains such as antigen-ligand binding partners and variable lymphocyte receptors.
Justin C, Boucher, Marco L, Davila
openaire   +2 more sources

Chimeric Antigen Receptors for the Tumour Microenvironment

2020
Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option.
Rosemary, Habib, Adnan, Nagrial, Kenneth, Micklethwaite, Kavitha, Gowrishankar   +3 more
openaire   +2 more sources

4-1BB Chimeric Antigen Receptors

The Cancer Journal, 2014
In addition to T-cell receptor signals, T lymphocytes require costimulatory signals for robust activation. Among these, those mediated by 4-1BB (CD137, TNFRSF9) are critical for tumor immunity. 4-1BB is expressed in T-cell receptor-activated lymphocytes as well as natural killer cells and other hematopoietic and nonhematopoietic cells.
Dario, Campana, Herbert, Schwarz, Chihaya, Imai   +2 more
openaire   +2 more sources

Structural Determinants of Chimeric Antigen Receptor Design

Critical Reviews in Immunology, 2021
Chimeric antigen receptor (CAR) T cell therapy consists of the gene transfer of a cassette encoding a receptor capable of redirecting the transduced T cell toward a specific cytotoxic response against tumor cells. The therapy has been providing a new perspective on some hematologic malignancies, such as CD19+ lymphomas and acute lympho-blastic leukemia.
Luiza, Abdo, Emmanuel Arthur, Aragão, Martín, Bonamino   +2 more
openaire   +2 more sources

Chimeric Antigen Receptors for Cancer Immunotherapy

2016
The adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) has emerged as a promising treatment for various lymphoid and solid malignancies. Patients treated with CAR-T cells have achieved dramatic responses and in some cases, complete tumor eradication.
Claudia, Geldres, Barbara, Savoldo, Gianpietro, Dotti   +2 more
openaire   +2 more sources

Imaging Chimeric Antigen Receptor (CAR) Activation

2020
The chimeric antigen receptor (CAR) has been extensively exploited in cancer immunotherapy. In spite of the success of CAR T cells in clinical applications, the molecular mechanism underlying CAR-T cell activation remains unclear. Key questions remain: how are CARs activated by tumor antigens?
Kendra A, Libby, Xiaolei, Su
openaire   +2 more sources